- ¥180bn
- ¥368bn
- ¥274bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.79 | ||
| PEG Ratio (f) | 0.55 | ||
| EPS Growth (f) | 16.41% | ||
| Dividend Yield (f) | 2.42% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.99 | ||
| Price to Tang. Book | 1.15 | ||
| Price to Free Cashflow | 76.28 | ||
| Price to Sales | 0.64 | ||
| EV to EBITDA | 9.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.61% | ||
| Return on Equity | 4.66% | ||
| Operating Margin | 6.31% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 165,615 | 208,859 | 227,934 | 259,594 | 273,710 | 306,594 | 333,882 | 12.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.05 | -42.11 | +97.24 | +33.59 | -28.78 | +45.17 | +0.07 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TOWA PHARMACEUTICAL CO., LTD. is engaged in the manufacture and sale of ethical pharmaceutical products. The Company operates through two segments. The Domestic segment manufactures pharmaceutical products and sells them directly to medical institutions through its sales offices, as well as to agents, pharmaceutical wholesalers and other pharmaceutical manufacturers. Through its subsidiaries, the Company engages in businesses such as the research and manufacture of active pharmaceutical ingredients, the production of soft capsules, and the planning, development, and contract manufacturing of health foods and pharmaceuticals. The Overseas segment consists of a holding company that consolidates the generic pharmaceutical business in Europe and the United States. Its group companies have research and development and manufacturing bases in Europe, and are engaged in the generic pharmaceutical sales business and contract research and development and manufacturing business.
Directors
- Itsuro Yoshida PRE (68)
- Masao Tanaka CEX (67)
- Kazuhiko Konno SMD (66)
- Yasushi Naito SEO (57)
- Yusuke Amano SEO
- Norikazu Inoue SEO
- Takayuki Kanno SEO
- Shigehiro Kubo SEO
- Sadayuki Morino SEO (67)
- Osamu UCHIKAWA SEO
- Masaji Morikawa DSL
- Shigeki Fujita EXO
- Muneyoshi Kaji EXO
- Shuichi Katsuki EXO
- Katsutoshi Kawamura EXO
- Shinya Kida EXO
- Toshikazu Kokubun EXO
- Mitsuhiro Matsumoto EXO
- Jun Matsuo EXO
- Yutaka Okuda EXO
- Kiyoto Onchi EXO
- Takeshi Sugiura EXO
- Koichi Tamura EXO
- Toshiyuki Tanaka EXO
- Tetsuo Yamashita EXO
- Toshio Shirakawa DRC (68)
- Norikazu Eiki IND (73)
- Kenryo Goto IND (63)
- Kaori Oishi IND (44)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- April 19th, 1957
- Public Since
- April 5th, 2004
- No. of Shareholders
- 5,069
- No. of Employees
- 4,923
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 49,227,867
- Address
- 2-11, Shimbashi-cho, KADOMA-SHI, 571-8580
- Web
- https://www.towayakuhin.co.jp
- Phone
- +81 669009100
- Auditors
- Ernst & Young ShinNihon LLC
Latest News for 4553
Upcoming Events for 4553
Q2 2027 TOWA PHARMACEUTICAL CO., LTD. Earnings Release
Q3 2027 Towa Pharmaceutical Co Ltd Earnings Release
Dividend For 4553.T - 45.0000 JPY
Similar to 4553
ASKA Pharmaceutical Holdings
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings
Tokyo Stock Exchange
CanBas
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 05:49 UTC, shares in TOWA PHARMACEUTICAL are trading at ¥3,660. This share price information is delayed by 15 minutes.
Shares in TOWA PHARMACEUTICAL last closed at ¥3,660 and the price had moved by +28.74% over the past 365 days. In terms of relative price strength the TOWA PHARMACEUTICAL share price has underperformed the Nikkei 225 Index by -4.86% over the past year.
The overall consensus recommendation for TOWA PHARMACEUTICAL is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe TOWA PHARMACEUTICAL dividend yield is 2.19% based on the trailing twelve month period.
Last year, TOWA PHARMACEUTICAL paid a total dividend of ¥80, and it currently has a trailing dividend yield of 2.19%.Looking ahead, the next dividend pay date is 2026-12-01.
We do not have data on when TOWA PHARMACEUTICAL is to next pay dividends. The historic dividend yield on TOWA PHARMACEUTICAL shares is currently 2.19%.
To buy shares in TOWA PHARMACEUTICAL you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥3,660, shares in TOWA PHARMACEUTICAL had a market capitalisation of ¥180bn.
Here are the trading details for TOWA PHARMACEUTICAL:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4553
Based on an overall assessment of its quality, value and momentum TOWA PHARMACEUTICAL is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in TOWA PHARMACEUTICAL is ¥5,350. That is 46.17% above the last closing price of ¥3,660.
Analysts covering TOWA PHARMACEUTICAL currently have a consensus Earnings Per Share (EPS) forecast of ¥470 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TOWA PHARMACEUTICAL. Over the past six months, its share price has underperformed the Nikkei 225 Index by -23.97%.
As of the last closing price of ¥3,660, shares in TOWA PHARMACEUTICAL were trading -5.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TOWA PHARMACEUTICAL PE ratio based on its reported earnings over the past 12 months is 7.79. The shares last closed at ¥3,660.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
TOWA PHARMACEUTICAL's management team is headed by:
- Itsuro Yoshida - PRE
- Masao Tanaka - CEX
- Kazuhiko Konno - SMD
- Yasushi Naito - SEO
- Yusuke Amano - SEO
- Norikazu Inoue - SEO
- Takayuki Kanno - SEO
- Shigehiro Kubo - SEO
- Sadayuki Morino - SEO
- Osamu UCHIKAWA - SEO
- Masaji Morikawa - DSL
- Shigeki Fujita - EXO
- Muneyoshi Kaji - EXO
- Shuichi Katsuki - EXO
- Katsutoshi Kawamura - EXO
- Shinya Kida - EXO
- Toshikazu Kokubun - EXO
- Mitsuhiro Matsumoto - EXO
- Jun Matsuo - EXO
- Yutaka Okuda - EXO
- Kiyoto Onchi - EXO
- Takeshi Sugiura - EXO
- Koichi Tamura - EXO
- Toshiyuki Tanaka - EXO
- Tetsuo Yamashita - EXO
- Toshio Shirakawa - DRC
- Norikazu Eiki - IND
- Kenryo Goto - IND
- Kaori Oishi - IND